Side Effects of Tofacitinib in Ulcerative Colitis
The most common side effects of tofacitinib in ulcerative colitis patients are nasopharyngitis (10-14%), elevated cholesterol levels (5-9%), headache (3-9%), upper respiratory tract infections (6-7%), increased creatine phosphokinase (3-7%), rash (3-6%), diarrhea (2-5%), and herpes zoster (1-5%), with the critical caveat that serious adverse events including herpes zoster, serious infections, and venous thromboembolism are dose-dependent and significantly higher at the 10 mg twice daily dose compared to 5 mg twice daily. 1
Common Adverse Reactions (≥5% incidence)
Based on FDA labeling data from controlled UC trials, the following adverse reactions occurred in ≥5% of patients and ≥1% more frequently than placebo 1:
During Maintenance Therapy (52-week trial):
- Nasopharyngitis: 10-14% (vs 6% placebo)
- Elevated cholesterol: 5-9% (vs 1% placebo)
- Headache: 3-9% (vs 6% placebo)
- Upper respiratory infections: 6-7% (vs 4% placebo)
- Increased creatine phosphokinase: 3-7% (vs 2% placebo)
- Rash: 3-6% (vs 4% placebo)
- Diarrhea: 2-5% (vs 3% placebo)
- Herpes zoster: 1-5% (vs 1% placebo)
During Induction Therapy (8-week trials):
- Headache
- Nasopharyngitis
- Elevated cholesterol
- Acne
- Increased creatine phosphokinase
- Pyrexia (fever)
Serious Adverse Events: Critical Dose-Dependent Risks
The FDA label explicitly warns that herpes zoster infections, serious infections, and non-melanoma skin cancers are dose-dependent, occurring more frequently at 10 mg twice daily versus 5 mg twice daily. 1 This is clinically crucial because the 2024 AGA guidelines note that approximately 25-29% of patients require maintenance at the higher 10 mg dose, and only 63% successfully recapture response when dose is re-escalated after de-escalation failure. 2
Infection-Related Adverse Events
From pooled clinical trial data (1,613 patient-years exposure) 3:
- Serious infections: 2.0 per 100 patient-years (95% CI: 1.4-2.8)
- Opportunistic infections: 1.3 per 100 patient-years (95% CI: 0.8-2.0)
- Herpes zoster: 4.1 per 100 patient-years (95% CI: 3.1-5.2)
- Maintenance trial showed dose-dependent increase: 1.0% (placebo) vs 2.1% (5 mg BID) vs 6.6% (10 mg BID) 3
- Tuberculosis reactivation: Reported in real-world studies 4
Critical clinical implication: The AGA guidelines emphasize that patients maintained on 10 mg twice daily require careful monitoring for herpes zoster and venous thromboembolism, with adoption of preventive strategies (including herpes zoster vaccination when feasible). 2
Cardiovascular and Thromboembolic Events
Five cases of pulmonary embolism were reported in patients taking 10 mg twice daily, including one fatality in a patient with advanced cancer. 1 From pooled trial data 3:
- Major adverse cardiovascular events (MACE): 0.2 per 100 patient-years (95% CI: 0.1-0.6)
- Venous thromboembolism: Included in serious adverse events monitoring
Important context: The FDA label references a post-marketing safety study in rheumatoid arthritis patients aged ≥50 years with cardiovascular risk factors showing increased risk of MACE and malignancy with tofacitinib 10 mg twice daily versus TNF antagonists. 5 However, post-hoc analyses in UC populations and Korean national data (1,816 patients) showed no significant difference in thromboembolic events between tofacitinib and anti-TNF therapy (P=0.151). 6
Malignancy Risk
- Malignancy (excluding NMSC): 0.7 per 100 patient-years (95% CI: 0.3-1.2)
- Non-melanoma skin cancer: 0.7 per 100 patient-years (95% CI: 0.3-1.2)
- During 8-week induction and 52-week maintenance studies: Zero cases of solid cancer or lymphoma in 1,220 patients
- Long-term extension study: Malignancies observed at both 5 mg and 10 mg doses
Other Serious Events
- Gastrointestinal perforations: 0.2 per 100 patient-years (95% CI: 0.0-0.5) 3
- Death: 0.2 per 100 patient-years (95% CI: 0.1-0.6) 3
- Hepatitis B or C reactivation: Possible in carriers 1
Real-World Safety Data
Korean national data (3-year follow-up, 521 tofacitinib patients) showed overall serious adverse event rates similar to anti-TNF therapy (4.41 vs 5.33 per 100 person-years, P=0.332). 6 Risk factors for serious adverse events included age ≥60 years and concomitant hypertension. 6
Laboratory Abnormalities
- Hyperlipidemia: Most common adverse event in real-world studies 7
- Cytopenias: Intermittent occurrences noted 7
- Elevated cholesterol: Dose-dependent (1% placebo vs 5% at 5mg BID vs 9% at 10mg BID) 1
High-Risk Populations Requiring Caution
Tofacitinib should be avoided or used cautiously in: 4
- Elderly patients (≥60 years)
- Patients with cardiovascular comorbidity or uncontrolled cardiac risk factors
- Previous thrombotic episodes or high venous thrombosis risk
- Previous malignancy
- Active smokers (European Medicines Agency caution)
Preventive Strategies
Baseline evaluation must include: 4
- Hepatitis B testing and management
- Latent tuberculosis screening and treatment
- Complete adult vaccination (including herpes zoster) when feasible before initiation
Comparative Safety Context
The 2024 AGA guidelines classify tofacitinib as "intermediate efficacy" alongside golimumab, ustekinumab, filgotinib, and mirikizumab, distinguishing it from "higher efficacy" agents like infliximab, vedolizumab, upadacitinib, and risankizumab. 2 Real-world comparative data suggests upadacitinib demonstrates stronger biochemical response but tofacitinib maintains acceptable safety when used appropriately. 7
The safety profile of tofacitinib in UC appears similar to that in rheumatoid arthritis and to biologic agents in UC, with the notable exception of higher herpes zoster incidence. 3